For millions of people living with a rare disease, the struggle is often twofold. There is the physical and emotional toll of the condition itself, and then there is the systemic silence that follows: the agonizing realization that because their condition affects so few people, there is little financial incentive for pharmaceutical companies to develop a cure.
This “profit gap” has historically left patients in a medical wilderness, where the search for a diagnosis can take years and the available treatments are often non-existent or repurposed from other fields without formal approval. However, a shift in methodology is underway. Researchers are increasingly turning to new therapeutic approaches for rare diseases through a framework known as translational science, aiming to bridge the gap between a laboratory discovery and a patient’s bedside.
At the heart of this movement is the effort to “translate” basic biological research into clinical reality. This approach is the central theme of an upcoming international symposium scheduled for April 22–24, 2026, at the Evangelische Akademie Tutzing. The event, hosted by the Research-for-Rare network—a coalition of German research consortia for rare diseases—aims to synchronize the efforts of geneticists, clinicians, and patient advocates to accelerate the delivery of life-altering therapies.
The Bridge of Translational Medicine
Translational medicine is not a single treatment, but a bidirectional philosophy of research. According to Thomas Klopstock, a professor at the Neurological Clinic of the LMU University Hospital Munich, the goal is to ensure that findings from basic research are directly converted into clinical applications. This means that a discovery about a specific protein or genetic mutation in a petri dish is rapidly tested for its potential to improve diagnostics or create new therapies for living patients.
Crucially, this process is not a one-way street. Klopstock notes that translational science also works in reverse: insights gained from treating patients in a clinic are fed back into basic research to refine scientific questions. This feedback loop ensures that laboratory research remains grounded in the actual needs of the patient, reducing the time it takes for a scientific breakthrough to develop into a medical reality.
The urgency of this approach is underscored by the sheer scale of the affected population. While each individual disease is “rare,” the collective number of people living with these conditions is staggering. In Germany alone, it is estimated that one in 20 people is affected by a rare disease. Because the vast majority of these conditions are genetically driven, translational medicine provides a direct path from identifying a genetic effect to understanding the disease mechanism and, eventually, developing a targeted therapy.
Drug Repurposing: A Shortcut to Treatment
One of the most promising strategies within this framework is “drug repurposing.” This involves identifying existing, approved medications that may be effective for a different condition than the one they were originally designed to treat. Unlike “off-label use,” where a doctor prescribes a drug for an unapproved use, drug repurposing seeks formal regulatory approval for the new indication.
For patients with rare diseases, This represents often the fastest route to relief. Claudia Finis, a health policy representative for the Deutsche Gesellschaft Osteogenesis Imperfecta Betroffene e.V.—a self-help organization for those with Osteogenesis Imperfecta (commonly known as “brittle bone disease”)—emphasizes that this approach prevents patients from having to “start from zero.”
The advantages of drug repurposing are primarily safety and speed. Because the drug has already passed rigorous safety trials for another condition, the risk of unforeseen toxicities is significantly lower. The development timeline is compressed because researchers can skip early-stage safety trials and move directly to efficacy tests within the specific patient group.
Comparing Traditional Development vs. Drug Repurposing
| Feature | New Chemical Entity (NCE) | Drug Repurposing |
|---|---|---|
| Safety Profile | Unknown; requires Phase I trials | Established via previous approvals |
| Development Time | 10–15 years on average | Significantly reduced |
| Research Cost | Extremely high (billions) | Lower; focuses on efficacy trials |
| Regulatory Path | Full approval cycle | Accelerated for new indication |
The Tension Between Profit and Patient Care
Despite the scientific promise, the path to repurposing is often blocked by economic hurdles. Finis argues that pharmaceutical companies frequently lack interest in pursuing new approvals for vintage drugs because the small patient populations associated with rare diseases do not offer the same profit margins as blockbuster medications for common ailments.
However, not all researchers share this pessimistic view of the industry. Markus Schülke, a professor of pediatric neurology at the Charité in Berlin, has seen evidence that the tide may be turning. His work has focused on the potential of Sildenafil—originally developed and approved as a treatment for erectile dysfunction—to provide positive effects for children suffering from Leigh Syndrome, a severe neurological disorder.
Schülke’s experience suggests that an increasing number of pharmaceutical companies are becoming interested in rare disease therapeutics. This shift may be driven by a better understanding of molecular mechanisms; by solving the puzzle of a rare genetic disease, researchers often uncover fundamental biological truths that can be applied to more common conditions, creating a “halo effect” of innovation that benefits the wider medical community.
Rare diseases are essentially an opportunity. Researching them helps us better understand molecular mechanisms, which frequently leads to broader innovations in medicine.
— Thomas Klopstock, Neurologist at LMU University Hospital
This perspective reframes rare diseases not as medical dead-ends, but as the frontier of precision medicine. By focusing on the smallest cohorts, scientists are learning how to tailor treatments to the individual’s genetic makeup, a skill that will eventually redefine how all diseases are treated.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next major milestone for this community will be the gathering of international experts in Tutzing in April 2026, where the Research-for-Rare network expects to present updated clinical data and new frameworks for public-private partnerships to further incentivize drug repurposing.
Do you or a loved one live with a rare condition? We invite you to share your experiences or questions in the comments below or share this article to help raise awareness.
